Cargando…

Glycoconjugate vaccines: classic and novel approaches

Glycoconjugate vaccines, obtained by carbohydrates covalently bound to protein carriers, have contributed to fight diseases such as meningitidis, pneumonia and typhoid fever. Despite new technologies such as RNA and adenovirus based vaccine have now reached the market, these approaches are unable to...

Descripción completa

Detalles Bibliográficos
Autor principal: Adamo, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225458/
https://www.ncbi.nlm.nih.gov/pubmed/34169357
http://dx.doi.org/10.1007/s10719-021-09997-5
_version_ 1783712095205851136
author Adamo, Roberto
author_facet Adamo, Roberto
author_sort Adamo, Roberto
collection PubMed
description Glycoconjugate vaccines, obtained by carbohydrates covalently bound to protein carriers, have contributed to fight diseases such as meningitidis, pneumonia and typhoid fever. Despite new technologies such as RNA and adenovirus based vaccine have now reached the market, these approaches are unable to target carbohydrates which are key virulence factors. This issue intends to provide an overview on relevant directions where the field is evolving and serve as starting point to increase interest in this exciting and fundamental part of vaccinology.
format Online
Article
Text
id pubmed-8225458
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-82254582021-06-25 Glycoconjugate vaccines: classic and novel approaches Adamo, Roberto Glycoconj J Editorial Glycoconjugate vaccines, obtained by carbohydrates covalently bound to protein carriers, have contributed to fight diseases such as meningitidis, pneumonia and typhoid fever. Despite new technologies such as RNA and adenovirus based vaccine have now reached the market, these approaches are unable to target carbohydrates which are key virulence factors. This issue intends to provide an overview on relevant directions where the field is evolving and serve as starting point to increase interest in this exciting and fundamental part of vaccinology. Springer US 2021-06-25 2021 /pmc/articles/PMC8225458/ /pubmed/34169357 http://dx.doi.org/10.1007/s10719-021-09997-5 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Editorial
Adamo, Roberto
Glycoconjugate vaccines: classic and novel approaches
title Glycoconjugate vaccines: classic and novel approaches
title_full Glycoconjugate vaccines: classic and novel approaches
title_fullStr Glycoconjugate vaccines: classic and novel approaches
title_full_unstemmed Glycoconjugate vaccines: classic and novel approaches
title_short Glycoconjugate vaccines: classic and novel approaches
title_sort glycoconjugate vaccines: classic and novel approaches
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225458/
https://www.ncbi.nlm.nih.gov/pubmed/34169357
http://dx.doi.org/10.1007/s10719-021-09997-5
work_keys_str_mv AT adamoroberto glycoconjugatevaccinesclassicandnovelapproaches